Quantcast

Latest Mylan Stories

2014-05-09 12:26:05

PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014, in New York. The presentation is scheduled to begin at 10:30 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An archived...

2014-05-09 08:26:49

PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-05-02 08:25:27

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 2, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding AstraZeneca PLC (NYSE: AZN), Boston Scientific Corporation (NYSE: BSX), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Illumina Inc. (NASDAQ: ILMN) and Mylan, Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-05-01 08:37:39

DUBLIN, May 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sdjlqk/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this...

2014-04-25 20:21:31

Mylan Seeks to Confirm Shared 180-Day Exclusivity PITTSBURGH, April 25, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA), challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex(®). FDA issued a decision holding that eligibility for 180 days of exclusivity is only available to an applicant who first filed a...

2014-04-18 20:21:09

PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone(®) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of...

2014-04-16 16:30:46

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE(TM) (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day), the generic version of Janssen Pharmaceuticals Inc.'s ORTHO EVRA®* (Norelgestromin / Ethinyl Estradiol Transdermal System 150/35 mcg per day). This product is indicated for the prevention of pregnancy in women who elect to use a transdermal patch...

2014-04-15 12:30:09

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This...

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...

2014-04-15 08:29:42

DUBLIN, April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(®) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(®) FE under its pending Abbreviated New Drug...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related